1. GE Healthcare and LightLab Imaging Inc. Collaborate on Cardiovascular Imaging

    GE Healthcare and LightLab Imaging Inc. Collaborate on Cardiovascular Imaging

    GE Healthcare and LightLab Imaging Inc. Collaborate on Cardiovascular Imaging

    Joint efforts focus on Optical Coherence Tomography (OCT)

    Barcelona, SPAIN and Westford, MA, USA; May 19, 2009: GE Healthcare, a global leader in healthcare solutions and LightLab Imaging Inc., a market leader in optical imaging, today announced a collaboration that enables improved workflow between GE Healthcare’s Innova® cardiovascular X-ray system and LightLab Imaging Inc.’s C7-XR™ Optical Coherence Tomography system. Both the C7-XR and Innova systems will be featured this week at the annual meeting of EuroPCR, the official congress of the EAPCI (European Association for Percutaneous Cardiovascular Interventions) in Barcelona, Spain. The LightLab C7-XR is available for purchase from LightLab in twenty countries in Europe, Asia, the Middle East and South America. GE’s Innova® portfolio is one of the world's most trusted families of all-digital cardiovascular imaging systems.

    GE Healthcare’s Innova X-ray imaging systems provide users with excellent image quality with industry leading dose efficiency. Built on GE's advanced Innova digital detector, the Innova system helps physicians clearly visualize fine vessels, precisely place stents and successfully perform critical procedures. Cardiologists in the cardiac cath lab use it when performing procedures to view and treat potential coronary artery blockages that could cause heart attacks or other serious cardiovascular damage. The system is designed to help provide cardiologists with more information than ever before, helping them to better diagnose and treat cardiovascular disease.

    "GE is constantly spearheading cutting edge technologies for the advancement of healthcare and Optical Coherence Tomography is the latest imaging tool that expands our footprint in the cardiovascular space," said Jayant Saha, General Manager, Interventional Global Marketing for GE Healthcare. "OCT is proving to be a great asset in increasing the clinical acumen in interventional cardiology. With LightLab Imaging Inc., a leading optical imaging solution provider, GE looks forward to offering the technological advances in the field of OCT to our joint customers and the patients they care for."

    LightLab Imaging’s next generation Optical Coherence Tomography System, the C7-XR™ can be directly installed in the cardiac catheterization lab or radiology suite alongside GE Innova X-ray system, enabling physicians to more readily incorporate OCT technology into their procedures.

    With OCT, a small optical imaging catheter is inserted into a vessel where near infrared light waves reflect off the internal microstructure within tissue or vessel walls. The reflected waves create extremely high-resolution cross-sectional images from within the artery to aid in the evaluation of disease and the management of targeted therapies. OCT is an important tool in selecting and assessing the performance of therapeutic options because it is designed to provide a more complete picture from inside the vessel. The C7-XR is a powerful high-resolution imaging system that is designed to simply and quickly provide intra-coronary images of extraordinary clarity.

    David Kolstad, President and CEO of LightLab Imaging, added, “We are very pleased to bring our most advanced platform, the C7-XR system to GE and LightLab’s joint customers. We believe that improving cath lab workflow, as well as the capabilities of these highly complementary imaging technologies, will benefit clinicians, patients and payors alike.”

    About GE Healthcare

    GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

    Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a US$17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com

    About LightLab Imaging

    LightLab Imaging, Inc., based in Westford MA is the world’s leading manufacturer and marketer of Optical Coherence Tomography for vascular and other applications. LightLab currently sells its OCT systems and imaging catheters in twenty countries in Europe, Asia, the Middle East and South America. It currently does not sell products in the United States. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patient’s wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. For more information, visit http://www.lightlabimaging.com/.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, significance of event data, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    For further information, please contact:

    GE Healthcare: Allison Cohen Media Relations +972.4.857-9290 allison.cohen@ge.com

    Lightlab Imaging Inc: Steve DiMattia Media Relations 1-646-201-5445 sdimattia@evcgroup.com

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. GE is constantly spearheading cutting edge technologies for the advancement of healthcare and Optical Coherence Tomography is the latest imaging tool that expands our footprint in the cardiovascular space.
    2. We are very pleased to bring our most advanced platform, the C7-XR system to GE and LightLab's joint customers. We believe that improving cath lab workflow, as well as the capabilities of these highly complementary imaging technologies, will benefit clinicians, patients and payors alike.
  3. Topics Mentioned